1Louis DN, Scheithauer BW, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee WK, eds. Tumours of the nervous system ; Pathology and genetics: WHO international classification of tumours. Lyon: IARC Press, 2000: 176-184.
2Shinozawa T, Xin L, Mattem J, et al. Immunohistochemical detection of cyclin a with reference to p53 expression in endometfial endometrioid carcinomas. Int Gyneco Pathol, 1997,16:348-353.
3Handa K, Yamakawa M, Takeda H, et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prodnosis. Int J Cancer, 1999, 84: 225-233.
3Nakabayashi H, Sakaguchi M, Katsuyama J, et al. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression [J]. J Neurooncol, 1995, 24(3): 209 -217.
4Ferraraccio F, Accardo M, Giangaspero F, et al. Recurrent and atypical meningiomas-a multiparametric study using Ki67 labelling index, AgNOR and DNA Feulgen staining [ J]. Clin Neuropathol,2003, 22(4): 187 - 192.
5Radner H, Blumcke I, Reifenberger G, et al. The new WHO classification of tumors of the nervous system 2000. pathology and genetics [J]. Pathologe, 2002, 23(4): 260 -283.
6vov Deimling A, Larson J, Wellenreuther R, et al. Clonal origin of recurrent meningiomas [ J]. Brain Pathol, 1999, 9 (4): 645 - 650.
7Strojnik T, Zidanik B, Kos J, et al. Cathepsins B and L are markers for clinicanlly invasive types of meningiomas [ J]. Neurosurgery, 2001,48(3): 598 - 605.
8Borovich B, Doron Y. Recurrence of intracranial meningiomas: the role played by regional multicentricity [J]. J Neurosurg, 1986, 64( 1 ): 58- 63.
9Kinjo T, al-Mefty O, Kanaan I. Grade zero removal of supratentorial convexity meningiomas [ J ]. Neurosurgery, 1993, 33 ( 3 ): 394 - 399.
